Publication of Results for the quarter and year ended 31/03/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals published its audited standalone financial results for Q4 FY25 (quarter ended 31 March 2025) and the full financial year ended 31 March 2025 in Business Standard (English) and Jai Hind (Gujarati) newspapers, as required under SEBI Listing Regulations. For FY25, total income from operations stood at Rs 3,679.39 lakhs, down sharply from Rs 7,738.81 lakhs in FY24, while net profit after tax fell to Rs 957.51 lakhs from Rs 1,853.72 lakhs. For Q4 FY25 alone, revenue was Rs 1,473.50 lakhs (vs Rs 1,226.07 lakhs in Q4 FY24) and net profit after tax was Rs 538.64 lakhs (vs Rs 398.59 lakhs). Basic EPS for FY25 was Rs 0.22 (vs Rs 4.23 in FY24), and Q4 EPS was Rs 0.42 (vs Rs 0.91 in Q4 FY24).
Sharp year-on-year decline in both revenue (~52%) and net profit (~48%) along with a steep fall in EPS is a negative signal for shareholders, though Q4 showed some sequential recovery versus the prior-year quarter. Investors should watch for management commentary on why full-year numbers contracted so steeply.